Wordt geladen...

Adverse Events Associated with Use of Digoxin Immune Fab Reported to the US Food and Drug Administration Adverse Event Reporting System, 1986–2019

BACKGROUND: Digoxin immune fab products, DigiBind and DigiFab, are antidotes for the treatment of patients with life-threatening or potentially life-threatening digoxin toxicity or overdose. Although approved by the US Food and Drug Administration (FDA) in 1986 (DigiBind) and 2001 (DigiFab), there r...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Drugs Real World Outcomes
Hoofdauteurs: Wei, Shaokui, Niu, Manette T., Dores, Graça M.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Springer International Publishing 2021
Onderwerpen:
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8128941/
https://ncbi.nlm.nih.gov/pubmed/33721285
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40801-021-00242-x
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!